Shiro Maeyama

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD)

Masato Yoneda, Masato Yoneda, Hironori Mawatari et al. · Digestive and Liver Disease · 2007 · 422 citations

Medicine, Internal Medicine, Pathology +15

Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling

Kento Imajo, Koji Fujita, Masato Yoneda et al. · Cell Metabolism · 2012 · 340 citations · Full text

Life Sciences, Endocrinology, Immunology +14

High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH

Masato Yoneda, Hironori Mawatari, Koji Fujita et al. · Journal of Gastroenterology · 2007 · 293 citations

Medicine, Pathology, Hepatology +13

Efficacy of ezetimibe for the treatment of non‐alcoholic steatohepatitis: An open‐label, pilot study

Masato Yoneda, Koji Fujita, Yuichi Nozaki et al. · Hepatology Research · 2010 · 138 citations

Medicine, Pharmacology, Pharmacotherapy +17

Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage

Masato Yoneda, Hironori Mawatari, Koji Fujita et al. · Journal of Gastroenterology · 2007 · 97 citations

Medicine, Internal Medicine, Pathology +16